In this respect, the GLP-1 analogue liraglutide, which was approved for the treatment of type 2 diabetes in Europe in 2009 and the USA in 2010, is 250 times cheaper than teduglutide, at an annual cost of USD 1200 per patient [67]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.